newsfilter
← Latest News
GlobeNewswire·

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

  • Verrica Pharmaceuticals Inc. announced that President & CEO Jayson Rieger will present at the Jefferies Global Healthcare Conference.
  • The presentation is scheduled for Thursday, June 4, 2026, at 11:05am ET in New York.
  • A live webcast of the event will be available via a provided link or the Investors/Presentations & Events section of Verrica's website.
  • A replay of the webcast will be posted shortly after the presentation for 90 days.
  • Verrica's product YCANTH (VP-102) is the only FDA-approved healthcare professional-administered treatment for molluscum contagiosum in patients aged two and older.
  • YCANTH (VP-102) is also in development for the treatment of common warts.
  • Verrica has a worldwide license agreement with Lytix Biopharma AS to develop VP-315 (ruxotemitide) for non-melanoma skin cancers.
  • Investor contact information is provided for John J Kirby, Interim CFO, Kevin Gardner of LifeSci Advisors.